Jordan A. Cafritz

Jordan Cafritz is a Senior Associate with the Firm’s Washington, D.C. office. While attending law school at American University he was an active member of the American University Business Law Review and worked as a Rule 16 attorney in the Criminal Justice Defense Clinic. After graduating from law school, Mr. Cafritz clerked for the Honorable Paul W. Grimm in the U.S. District Court for the District of Maryland.

In Karsan Value Fund v. Kostecki Brokerage Pty, Ltd. et al., C.A. No. 2021-0899-LWW (Delaware Chancery), Mr. Cafritz played a lead role in securing a $9.5 million common fund for the minority stockholders in connection with a controller buyout – a $1.90 per share (75%) increase on top of the original merger consideration of $2.55 per share.

In Jacobs v. Meghji, et al., C.A. No. 2019-1022-MTZ (Delaware Chancery), Mr. Cafritz played a lead role in challenging a series of unfair equity transactions imposed on Infrastructure Energy Alternatives Inc. The resulting settlement led to the issuance of new preferred stock that fundamentally revised the capital structure of the company and paved the way for a $1.1bn acquisition of the company.

In Teuza – A Fairchild Technology Venture, Ltd., et al. v. Lindon, et al., C.A. No. 2022-0130-BWD (Delaware Chancery), Mr. Cafritz played a lead role in challenging the 2021 sale of Bioness, Inc. to Bioventus, in which the company's controlling stockholders were alleged to have steered the sale process to benefit themselves at the expense of the minority shareholders. The resulting settlement provided an $8.9 million all-cash common fund for the minority shareholders, with the Court of Chancery finding counsel "experienced and well qualified" and recognizing the "excellent representation” that the class received.